1312684-75-5

Upstream product

• 1374193-76-6 N-(1-(8-(3,5-difluorophenyl)quinolin-7-yl)ethyl)-2-methylpropane-2-sulfinamide 
• 1374193-62-0 (E)-N-((8-(3,5-difluorophenyl)quinolin-7-yl)methylene)-2-methylpropane-2-sulfinamide 
• 1352717-46-4 methyl 8-(((trifluoromethyl)sulfonyl)oxy)quinoline-7-carboxylate 
• 73776-20-2 8-hydroxyquinoline-7-carboxylic acid methyl ester 
• 1312684-74-4 C₁₈H₁₅F₂NO₃S 
• 1312684-73-3 7-(1-azidoethyl)-8-(3,5-difluorophenyl)quinoline 
• 1312684-71-1 1-[8-(3,5-difluorophenyl)quinolin-7-yl]ethanol 
• 1312684-70-0 1-[8-(3,5-difluorophenyl)quinolin-7-yl]ethanone 
• 1312684-68-6 7-{[methoxy(methyl)amino]carbonyl}quinolin-8-yl trifluoromethanesulfonate 
• 1312684-67-5 8-hydroxy-N-methoxy-N-methylquinoline-7-carboxamide 
• 19829-79-9 8-hydroxy-7-quinolinecarboxylic acid 

Downstream Products

• 1312682-38-4 N-(1-(8-(3,5-difluorophenyl)quinolin-7-yl)ethyl)-9H-purin-6-amine 
• 1374193-98-2 4-amino-6-((1-(8-(3,5-difluorophenyl)-7-quinolinyl)ethyl)amino)-5-pyrimidinecarbonitrile 

Relevant academic research and scientific papers

5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention aLso enables methods for treating cancers that are mediated, dependent on or associated with pi 105 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo- dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS

The present invention provides fused aryl and heteroaryl derivatives of Formula I that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases